Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmacyte Biotech Inc (NQ: PMCB )

2.190 -0.020 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharmacyte Biotech Inc

< Previous 1 2 Next >
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.